GlassScriptPhysician profile
Ahmed T Robbie
NPI 1801826052
$580.81
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $129.22 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $99.34 | 2019-2020 | |
| Lilly USA, LLC | $62.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.99 | 2019 | |
| Amgen INC. | $43.06 | 2019 | |
| Genzyme Corporation | $38.65 | 2019 | |
| Supernus Pharmaceuticals, INC. | $37.50 | 2019 | |
| Pfizer INC. | $32.58 | 2019 | |
| Harmony Biosciences LLC | $24.00 | 2020 | |
| Livanova USA, INC. | $22.02 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.56 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.09 | 2019 | |
| Boston Scientific Corporation | $11.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Robbie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.